

CITATION REPORT

List of articles citing

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis

DOI: 10.1001/archdermatol.2011.191
Archives of Dermatology, 2011, 147, 1261-7.

Source: <https://exaly.com/paper-pdf/52212709/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	[What's new in dermatological therapy?]. 2011 , 138 Suppl 4, S263-72		
110	[What's new in internal medicine?]. 2012 , 139 Suppl 5, S194-201		
109	Tratamiento del lupus eritematoso cutáneo resistente. 2012 , 13, 77-84		
108	Antimalarials: Reversing the autoimmune ßal-area. 2012 , 7, 97-101		
107	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. 2012 , 8, 522-33		145
106	Cutaneous lupus erythematosus. 2012 , 25, 99-111		10
105	SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. 2013 , 9, 281-96		26
104	Cutaneous lupus erythematosus: diagnosis and treatment. 2013 , 27, 391-404		152
103	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. 2013 , 9, 281-296		1
102	Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis. 2013 , 2, 48-57		
101	Is there an effective treatment for late-onset systemic lupus erythematosus?. 2013 , 9, 437-450		
100	Antipalúdicos de síntesis en dermatología. 2013 , 47, 1-8		
99	Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. 2013 , 12, 694-702		37
98	Update on pathogenesis and treatment of CLE. 2013 , 25, 584-90		15
97	Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus. 2013 , 169, 653-9		19
96	Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. 2013 , 149, 104-6		23
95	Antipalúdicos de síntesis en dermatología. 2013 , 8, 1-7		

94	Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios. 2014 , 105, 243-252	27
93	Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. 2014 , 47, 148-62	68
92	Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. 2014 , 171, 571-9	56
91	Pragmatic approaches to therapy for systemic lupus erythematosus. 2014 , 10, 97-107	65
90	Severe Skin Diseases in Children. 2014 ,	
89	The immunopathology of cutaneous lupus erythematosus. 2014 , 40, 455-74, viii	20
88	Antimalarials in dermatology: mechanism of action, indications, and side effects. 2014 , 105, 243-52	14
87	Influencia del tabaco en el tratamiento de los pacientes con lupus eritematoso cutáneo. 2014 , 29, 327-328	
86	Cutaneous Lupus Erythematosus. 2014 , 523-530	1
85	Manifestaciones cutáneas del lupus eritematoso. 2015 , 49, 1-14	0
84	Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. 2015 , 70, 1608-21	258
83	Current and future treatment options for cutaneous lupus erythematosus. 2015 , 3, 777-786	
82	Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?. 2015 , 95, 596-9	9
81	A highlight from the LUPUS 2014 meeting: eight great ideas. 2015 , 2, e000087	10
80	Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?. 2015 , 27, 213-5	6
79	Review of treatment for discoid lupus erythematosus. 2016 , 29, 274-83	30
78	Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. 2016 , 28, 453-9	47
77	Connective Tissue Disease. 2016 ,	1

76	Conventional Treatment of Systemic Lupus Erythematosus. 2016 , 213-238		
75	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. 2016 , 146, 413.e1-413.e14		1
74	Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea. 2016 , 34, 243-50		7
73	Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. 2016 , 12, 1109-21		10
72	[Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management]. 2016 , 146, 413.e1-14		10
71	Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. 2016 , 17, 135-46		62
70	Cutaneous Lupus Erythematosus: Current Treatment Options. 2016 , 2, 36-48		4
69	Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. 2017 , 177, 188-196		45
68	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. 2017 , 76, 1176-1182		29
67	Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 791-799	9.5	54
66	Quinacrine Suppresses Tumor Necrosis Factor- α and IFN- γ in Dermatomyositis and Cutaneous Lupus Erythematosus. 2017 , 18, S57-S63		21
65	Update on sunscreens distributed by major US retailers that meet American Academy of Dermatology recommendations. 2017 , 77, 377-379		4
64	The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. 2017 , 77, 374-377		10
63	The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. 2017 , 3, 189-194		23
62	S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). 2017 , 31, 389-404		75
61	Mepacrine as successful monotherapy for refractory Jessner-Kanof disease: still an important drug in the dermatologic armamentarium. 2017 , 28, 276-278		2
60	IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. 2017 , 174, 63-72		57
59	Lupus community panel proposals for optimising clinical trials: 2018. 2018 , 5, e000258		43

58	Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. 2018 , 27, 1718-1722	16
57	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. 2018 , 57, e1-e45	150
56	Chloroquine improves the response to ischemic muscle injury and increases HMGB1 after arterial ligation. 2018 , 67, 910-921	9
55	Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. 2018 , 78, 107-114.e1	24
54	Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. 2018 , 78, 100-106.e1	30
53	Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. 2018 , 4, 789-793	3
52	[What the rheumatologist can learn from the dermatologist-or: nobody can separate good friends : Interfaces of both domains]. 2018 , 77, 484-492	
51	Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. 2018 , 79, 1053-1060.e3	4
50	An atypical clinical presentation of alopecia in 2 patients with systemic lupus erythematosus. 2019 , 5, 953-956	2
49	Cutaneous lupus erythematosus: A review of the literature. 2019 , 5, 320-329	10
48	Effectiveness of Quinacrine (Mepacrine) in Photosensitive Autoimmune Diseases, Lupus Erythematosus, and Dermatomyositis: Report on 38 Cases and Literature Review. 2019 , 34, 34-43	3
47	Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFN γ Production From Patients Affected With Cutaneous Lupus Erythematosus. 2019 , 10, 275	19
46	Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine. 2019 , 1, 593-599	14
45	Pathogenesis of Cutaneous Lupus. 2019 , 305-316.e4	1
44	Ocular, Aural, and Oral Manifestations of Lupus. 2019 , 556-565	1
43	Management of Cutaneous Lupus Erythematosus. 2019 , 719-726	
42	Connective Tissue Disease: Current Concepts. 2019 , 37, 37-48	4
41	Increased Myeloid Dendritic Cells and TNF- α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. 2019 , 139, 324-332	20

40	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. 2020 , 82, 709-722	12
39	Management of cutaneous manifestations of lupus erythematosus: A systematic review. 2020 , 50, 95-127	18
38	Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. 2020 , 236, 467-476	5
37	Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1777-1785	9.5 1
36	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. 2020 , 7,	1
35	Dendritic cells as predictive markers of responsiveness to hydroxychloroquine treatment in primary cicatricial alopecia patients. 2020 , 33, e14509	
34	Manifestaciones cutáneas del lupus eritematoso. 2020 , 54, 1-17	
33	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. 2020 , 10, 7908	24
32	Antimalarial Agents. 2021 , 234-244.e4	1
31	Familiar Dermatologic Drugs as Therapies for COVID-19. 2021 , 112, 118-126	1
30	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. 2021 , 13, 1759720X211002595	2
29	Familiar dermatologic drugs as therapies for COVID-19. 2021 , 112, 118-126	0
28	Recent Insight on the Management of Lupus Erythematosus Alopecia. 2021 , 14, 333-347	1
27	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. 2021 , 9, 431	1
26	Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus. 2021 , 9, 429	5
25	Identification of key genes and pathways in discoid lupus skin via bioinformatics analysis. 2021 , 100, e25433	0
24	Immunological and clinical heterogeneity in cutaneous lupus erythematosus. 2021 , 185, 480-481	1
23	Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. 2021 , 123, 102707	2

22	Lupus Erythematosus. 2015 , 547-560	1
21	SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. 2020 , 21, e927304	4
20	Comment je traite une atteinte cutanée lupique réfractaire aux antipaludéens de synthèse ?. 2013 , 241-245	
19	Measurement of disease severity in cutaneous autoimmune diseases. 2013 , 5, 19	3
18	Connective Tissue Disease. 2014 , 91-122	
17	Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report. 2017 , 05, 25-33	
16	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent.	1
15	Cutaneous Lupus. 2022 , 25-52	
14	Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.. 2022 , 9612033221084093	0
13	Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need.. 2021 , 8,	0
12	Image_1.TIF. 2019 ,	
11	Image_2.TIF. 2019 ,	
10	Image_3.TIF. 2019 ,	
9	Image_4.TIF. 2019 ,	
8	Image_5.TIF. 2019 ,	
7	Table_1.xlsx. 2019 ,	
6	Cutaneous lupus erythematosus: pathogenesis, clinical pattern, diagnostics, therapy. <i>Vestnik Dermatologii i Venerologii</i> , 2015 , 91, 24-33	0.4 0
5	Collagen Vascular Disorders. 2016 , 509-539.e8	

4	Antimalarial agents. 2013 , 241-251.e3		3
3	Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient responses to antimalarials.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	0
2	Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature. Volume 15, 1815-1831		1
1	The State Of Current Management Of The Heightened Risk For Atherosclerotic Cardiovascular Events In An Established Cohort Of Patients With Lupus Erythematosus.		0